KR20010034442A - 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제 - Google Patents

치환된 옥소아자헤테로사이클릴 인자 Xa 억제제 Download PDF

Info

Publication number
KR20010034442A
KR20010034442A KR1020007008221A KR20007008221A KR20010034442A KR 20010034442 A KR20010034442 A KR 20010034442A KR 1020007008221 A KR1020007008221 A KR 1020007008221A KR 20007008221 A KR20007008221 A KR 20007008221A KR 20010034442 A KR20010034442 A KR 20010034442A
Authority
KR
South Korea
Prior art keywords
ylmethyl
chloro
piperazin
thiophen
amino
Prior art date
Application number
KR1020007008221A
Other languages
English (en)
Korean (ko)
Inventor
유잉윌리엄알
벡커마이클알
최-슬레데스키용미
폴즈헤인즈더블유
헤웨이
콘돈스티븐엠
데이비스로더릭에스
하니바바라에이
스파다알프레드피
번스크리스토퍼제이
지앙존제트
리아이웬
마이어즈마이클알
라우완에프
폴리그레고리비
Original Assignee
아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 filed Critical 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드
Publication of KR20010034442A publication Critical patent/KR20010034442A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
KR1020007008221A 1998-01-27 1999-01-27 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제 KR20010034442A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7270798P 1998-01-27 1998-01-27
US60/072,707 1998-01-27
PCT/US1999/001682 WO1999037304A1 (en) 1998-01-27 1999-01-27 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
KR20010034442A true KR20010034442A (ko) 2001-04-25

Family

ID=22109280

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007008221A KR20010034442A (ko) 1998-01-27 1999-01-27 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제

Country Status (25)

Country Link
US (1) US7612075B2 (US07612075-20091103-C00056.png)
EP (1) EP1051176B1 (US07612075-20091103-C00056.png)
JP (1) JP4676613B2 (US07612075-20091103-C00056.png)
KR (1) KR20010034442A (US07612075-20091103-C00056.png)
CN (1) CN1291892A (US07612075-20091103-C00056.png)
AP (1) AP2000001889A0 (US07612075-20091103-C00056.png)
AT (1) ATE346050T1 (US07612075-20091103-C00056.png)
AU (1) AU745425B2 (US07612075-20091103-C00056.png)
BG (1) BG104633A (US07612075-20091103-C00056.png)
BR (1) BR9907300A (US07612075-20091103-C00056.png)
CA (1) CA2319198C (US07612075-20091103-C00056.png)
DE (1) DE69934093T2 (US07612075-20091103-C00056.png)
EA (1) EA200000768A1 (US07612075-20091103-C00056.png)
EE (1) EE200000435A (US07612075-20091103-C00056.png)
HU (1) HUP0101810A3 (US07612075-20091103-C00056.png)
IL (2) IL137517A0 (US07612075-20091103-C00056.png)
IS (1) IS5574A (US07612075-20091103-C00056.png)
NO (1) NO20003808L (US07612075-20091103-C00056.png)
PL (1) PL342243A1 (US07612075-20091103-C00056.png)
SK (1) SK11082000A3 (US07612075-20091103-C00056.png)
TR (1) TR200002182T2 (US07612075-20091103-C00056.png)
UA (1) UA59433C2 (US07612075-20091103-C00056.png)
WO (1) WO1999037304A1 (US07612075-20091103-C00056.png)
YU (1) YU47600A (US07612075-20091103-C00056.png)
ZA (1) ZA99607B (US07612075-20091103-C00056.png)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9280698A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
CN1290254A (zh) * 1998-02-05 2001-04-04 武田药品工业株式会社 氨磺酰衍生物及其制备和用途
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US6747023B1 (en) * 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
JP2003529531A (ja) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルXa因子阻害剤
WO2000039102A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
ATE325114T1 (de) 1999-06-22 2006-06-15 Takeda Pharmaceutical Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
EE200200045A (et) * 1999-07-28 2003-06-16 Aventis Pharmaceuticals Products Inc. Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
AU2002211280A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Piperazin-2-one amides as inhibitors of factor Xa
EP1340753B1 (en) 2000-11-08 2006-01-11 Takeda Pharmaceutical Company Limited Carbamate derivatives, process for producing the same and use thereof
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
NZ540234A (en) 2001-04-18 2007-01-26 Euro Celtique Sa Nociceptin analogs for the treatment of pain
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1604982A1 (en) 2001-07-02 2005-12-14 AstraZeneca AB Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
DE10137163A1 (de) 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
DE60234354D1 (de) * 2001-08-24 2009-12-24 Univ Yale Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
KR20040101520A (ko) 2002-04-16 2004-12-02 데이진 가부시키가이샤 Ccr3 길항작용을 갖는 피페리딘 유도체
WO2003091245A1 (fr) 2002-04-25 2003-11-06 Teijin Limited Derives de piperidine 4,4 disubstitues a antagonisme pour ccr3
KR20030084444A (ko) * 2002-04-26 2003-11-01 주식회사 파나진 Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
JP4744149B2 (ja) 2002-12-03 2011-08-10 ファーマサイクリックス インコーポレイテッド 第viia因子阻害剤としての2−(2−ヒドロキシビフェニル−3−イル)−1h−ベンゾイミダゾール−5−カルボキサミジン誘導体
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
PL1641775T3 (pl) 2003-07-03 2009-07-31 Euro Celtique Sa Pochodne 2-pirydynoalkin użyteczne do leczenia bólu
EP1648878B9 (en) 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2545261C (en) 2003-11-17 2013-07-23 Boehringer Ingelheim International Gmbh Piperidine-substituted indoles- or heteroderivatives thereof
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1722792A1 (de) * 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
PL1784402T3 (pl) * 2004-09-03 2011-12-30 Yuhan Corp Pochodne pirolo[3,2-c]pirydyny oraz sposoby ich wytwarzania
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006055187A1 (en) 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US7919495B2 (en) 2005-02-17 2011-04-05 Astellas Pharma, Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
ATE531706T1 (de) 2005-04-30 2011-11-15 Boehringer Ingelheim Int Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2006270548A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US7544685B2 (en) 2005-08-17 2009-06-09 H. Lundbeck A/S 2,3-dihydroindole compounds
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
BRPI0616574A2 (pt) 2005-09-27 2009-11-24 Shionogi & Co derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
DK1934208T3 (da) 2005-10-04 2011-07-18 Bayer Schering Pharma Ag Ny polymorf form af 5-chlor-N-({(5S)-2-0x0-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
HUE040020T2 (hu) 2005-10-25 2019-02-28 Kalypsys Inc PPAR modulátorok sói és eljárások metabolikus betegségek kezelésére
WO2007080430A1 (en) * 2006-01-16 2007-07-19 Generics [Uk] Limited Novel process
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
KR101129868B1 (ko) * 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
WO2008049874A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
JP5372913B2 (ja) 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
AU2008243874B2 (en) 2007-04-27 2012-01-19 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
CA2695998A1 (en) * 2007-07-19 2009-01-22 F. Hoffmann-La Roche Ag Novel heterocyclyl compounds
WO2009024823A2 (en) 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090163508A1 (en) * 2007-10-10 2009-06-25 Takeda Pharmaceutical Company Limited Amide compound
JP2011500767A (ja) 2007-10-26 2011-01-06 グラクソ グループ リミテッド P2x7モジュレータとしての4−ベンゾイル−1−置換ピペラジン−2−オン誘導体
KR100967171B1 (ko) 2007-12-26 2010-07-05 재단법인서울대학교산학협력재단 Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법
DK2264009T3 (en) 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
EP2285305A2 (en) 2008-05-27 2011-02-23 Maquet Cardiovascular LLC Surgical instrument and method
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
CA2746004C (en) 2008-12-03 2017-06-06 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2745952A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
CA2747925A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
JP2012513435A (ja) 2008-12-23 2012-06-14 エフ.ホフマン−ラ ロシュ アーゲー P2x7調節薬としてのジヒドロピリドンアミド
BRPI0923498A2 (pt) 2008-12-23 2019-09-24 Hoffmann La Roche amidos de diidropiridona como moduladores de p2x7
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2415763B1 (en) 2009-03-30 2016-01-27 Ube Industries, Ltd. Pharmaceutical composition for treating or preventing glaucoma
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
EP2536702A4 (en) 2010-02-18 2013-07-10 Astrazeneca Ab NEW CRYSTALLINE FORM OF A CYCLOPROPYLBENZAMIDE DERIVATIVE
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102552274B (zh) * 2010-11-12 2013-10-23 姚雪彪 动点马达蛋白小分子抑制剂在抑制肿瘤细胞增殖中的应用
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
CN105693712A (zh) 2011-06-22 2016-06-22 普渡制药公司 包含二羟基取代基的trpv1拮抗剂及其用途
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2824806B1 (en) * 2013-07-09 2020-03-04 ABB Schweiz AG Ship's propulsion unit
WO2015168286A1 (en) 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
MX2017016875A (es) 2015-06-26 2018-04-24 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1.
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
UA122423C2 (uk) 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
MA46690A (fr) 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3535267B1 (en) 2016-11-02 2020-12-30 Janssen Pharmaceutica NV [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
US11053248B2 (en) 2016-11-02 2021-07-06 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
US11560372B2 (en) 2017-04-18 2023-01-24 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
CN116606271B (zh) * 2023-07-21 2023-09-29 北京百力格生物科技有限公司 一种3,6-二氯偏苯三酸酐的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877227A (en) * 1959-03-10 Chichi
GB808046A (en) * 1955-12-13 1959-01-28 Roche Products Ltd Novel substituted pyridone-acetic acid derivatives and process for the manufacture thereof
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
JPS49110680A (US07612075-20091103-C00056.png) * 1973-03-12 1974-10-22
JPS5793962A (en) * 1980-12-01 1982-06-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5120718A (en) * 1991-06-13 1992-06-09 Abbott Laboratories Candida acid protease inhibiting compounds
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
AU691361B2 (en) * 1994-12-01 1998-05-14 Toyama Chemical Co. Ltd. Novel 2,3-diketopiperazine derivative or salt thereof
GB9508622D0 (en) * 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
CA2249641A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69729583T2 (de) * 1996-04-17 2005-06-09 Bristol-Myers Squibb Pharma Co. N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
IL128428A0 (en) * 1996-08-14 2000-01-31 Zeneca Ltd Substituted pyrimidine derivatives and their pharmaceutical use
AU4172397A (en) * 1996-09-06 1998-03-26 Biochem Pharma Inc. Lactam inhibitors of thrombin
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
EP0977773A1 (en) * 1997-04-14 2000-02-09 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2002513412A (ja) * 1997-04-14 2002-05-08 シーオーアール セラピューティクス インコーポレイテッド 選択的Xa因子阻害剤
JP2001521524A (ja) 1997-04-14 2001-11-06 シーオーアール セラピューティクス インコーポレイテッド 選択的Xa因子阻害剤
CA2285685A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
AU7453498A (en) * 1997-05-30 1998-12-30 Takeda Chemical Industries Ltd. Sulfonamide derivatives, their production and use
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
GB9715892D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU9280698A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
WO1999033805A1 (fr) * 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Composes aromatiques presentant des groupements amino cycliques ou leur sels
CN1290254A (zh) * 1998-02-05 2001-04-04 武田药品工业株式会社 氨磺酰衍生物及其制备和用途
JP2000204081A (ja) * 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
DE19835950A1 (de) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinonderivate

Also Published As

Publication number Publication date
AP2000001889A0 (en) 2000-09-30
HUP0101810A2 (hu) 2002-04-29
EE200000435A (et) 2002-02-15
BG104633A (bg) 2001-03-30
IL137517A (en) 2006-12-10
NO20003808L (no) 2000-09-26
CA2319198C (en) 2011-02-22
ZA99607B (en) 1999-07-27
EP1051176A4 (en) 2002-06-12
EP1051176A1 (en) 2000-11-15
EP1051176B1 (en) 2006-11-22
JP2002501024A (ja) 2002-01-15
JP4676613B2 (ja) 2011-04-27
YU47600A (sh) 2002-09-19
US7612075B2 (en) 2009-11-03
CN1291892A (zh) 2001-04-18
IL137517A0 (en) 2001-07-24
HUP0101810A3 (en) 2002-05-28
NO20003808D0 (no) 2000-07-25
EA200000768A1 (ru) 2001-06-25
WO1999037304A1 (en) 1999-07-29
PL342243A1 (en) 2001-06-04
IS5574A (is) 2000-07-25
AU2653399A (en) 1999-08-09
DE69934093T2 (de) 2007-06-21
UA59433C2 (uk) 2003-09-15
DE69934093D1 (de) 2007-01-04
CA2319198A1 (en) 1999-07-29
TR200002182T2 (tr) 2000-12-21
AU745425B2 (en) 2002-03-21
BR9907300A (pt) 2000-10-24
SK11082000A3 (sk) 2001-01-18
ATE346050T1 (de) 2006-12-15
US20040102450A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
KR20010034442A (ko) 치환된 옥소아자헤테로사이클릴 인자 Xa 억제제
JP4829449B2 (ja) 置換オキソアザヘテロシクリル化合物
US6281227B1 (en) Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
JP2003529531A (ja) 置換オキソアザへテロシクリルXa因子阻害剤
EP0853618A1 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n- (aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
EP0944386B1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
MXPA00007250A (en) SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
CZ20002728A3 (cs) Substituované oxoazaheterocyklylové inhibitory faktoru Xa, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
CZ20004497A3 (en) Sulfonyl- or sulfonylamino-N-(heteroaralkyl)azaheterocyclylamide derivatives and pharmaceutical preparation containing thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid